Global Assets Advisory LLC Purchases Shares of 14,900 TransMedics Group, Inc. (NASDAQ:TMDX)

Global Assets Advisory LLC bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 14,900 shares of the company's stock, valued at approximately $1,049,000.

Several other large investors also recently added to or reduced their stakes in the business. NBC Securities Inc. bought a new position in shares of TransMedics Group during the 1st quarter valued at $25,000. Atlas Capital Advisors Inc. bought a new position in TransMedics Group during the fourth quarter valued at about $31,000. AlphaQuest LLC bought a new position in TransMedics Group during the fourth quarter valued at about $52,000. Rakuten Securities Inc. lifted its position in shares of TransMedics Group by 68.3% in the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock worth $84,000 after buying an additional 550 shares during the last quarter. Finally, Sava Infond d.o.o. bought a new stake in shares of TransMedics Group during the 4th quarter worth about $94,000. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TMDX has been the topic of a number of recent analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Oppenheimer increased their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $127.33.

TransMedics Group Stock Performance

Shares of TransMedics Group stock traded up $1.48 during midday trading on Thursday, hitting $130.06. The company had a trading volume of 440,636 shares, compared to its average volume of 1,367,806. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The business's 50 day simple moving average is $116.81 and its two-hundred day simple moving average is $85.30. The stock has a market cap of $4.40 billion, a PE ratio of 95.63 and a beta of 2.10. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The business's revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.35 EPS. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now owns 732 shares of the company's stock, valued at $84,641.16. The trade was a 89.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David Weill sold 732 shares of the firm's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director now directly owns 12,134 shares of the company's stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,418 shares of company stock worth $1,512,613 over the last three months. Company insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.